乳腺同侧双原发癌28例患者的临床特征及预后

发布时间：2018-04-22 21:12

本文选题：乳腺肿瘤 + 同侧双原发乳腺癌　；参考：《肿瘤》2017年02期

【摘要】：目的 :探讨乳腺同侧双原发癌的临床病理特征及预后。方法 :回顾性分析2006年1月—2008年1月经病理确诊的28例乳腺同侧双原发癌患者的病历及随访资料。结果 :MRI对乳腺同侧双发肿瘤的检出率最高(90%)。双肿瘤的病理类型一致率为64%。其中,10例患者的2个肿瘤均接受了免疫组织化学检查,雌激素受体和孕激素受体表达状态均相同,但Ki-67和表皮生长因子受体2表达状态存在差异,病理分子分型一致率为70%。预后的单因素分析结果显示,肿瘤分期(P=0.004)和雌激素受体表达状态(P=0.000)与总生存时间相关;肿瘤分期(P=0.003)、腋窝淋巴结转移状态(P=0.032)和雌激素受体表达状态(P=0.022)与无病生存时间相关。预后的多因素分析结果显示,肿瘤分期是乳腺同侧双原发癌预后的独立影响因素。结论 :乳腺同侧双原发癌病理类型的一致率较高,肿瘤分期是独立的预后影响因素。
[Abstract]:Objective: To investigate the clinicopathological features and prognosis of breast identical double primary carcinoma of the breast. Methods: a retrospective analysis of 28 cases of breast identical double primary carcinoma in 1 months from January 2006 to 2008 was reviewed and followed up. Results: the detection rate of MRI for the same side of the breast was the highest (90%). The pathological type of double tumor was 64%. Among the 10 patients, 2 of the 10 patients received immunohistochemical examination. The expression of estrogen receptor and progesterone receptor were all the same, but the expression of Ki-67 and epidermal growth factor receptor 2 was different. The consistent rate of pathological molecular typing was a single factor analysis of 70%. prognosis, tumor staging (P=0.004) and estrogen receptor table. P=0.000 was associated with total survival time; tumor staging (P=0.003), axillary lymph node metastasis state (P=0.032) and estrogen receptor expression state (P=0.022) were associated with disease-free survival time. Multivariate analysis of prognostic factors showed that tumor staging was an independent prognostic factor for breast identical double primary carcinoma. Conclusion: breast ipsilateral double primor The coincidence rate of pathological types was higher, and tumor stage was an independent prognostic factor.

【作者单位】：天津医科大学肿瘤医院乳腺二科国家肿瘤临床医学研究中心天津市肿瘤防治重点实验室天津市恶性肿瘤临床医学研究中心乳腺癌防治教育部重点实验室;
【基金】：天津市应用基础与前沿技术研究计划(编号:14JCYBJC24900)~~
【分类号】：R737.9

【相似文献】